SOCIO-DEMOGRAPHIC CHARACTERISTICS AND REPORTED PSY-CHO-MEDICAL SYMPTOMS FOR CHILDREN WITH RARE DISEASES. A COMPARATIVE STUDY BETWEEN PATIENTS WITH PHENYLKE-TONURIA, CYSTIC FIBROSIS AND HYPOTHYROIDISM

Authors

  • Magdalena IORGA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Diana MURARU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ana-Simona DROCHIOI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • F.D. PETRARIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Dana-Teodora ANTON-PĂDURARU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Keywords:

CHILD, CYSTIC FIBROSIS, HYPO-THYROIDISM, PHENYL-KETONURIA

Abstract

Rare diseases have great impact on both patients and family members’ life. The aim of the study was to identify socio-demographic characteristics and factors related to psychological and medical condition for pediatric patients diagnosed with phenylketonuria, cystic fibrosis and hypothyroidism. Material and methods: 37 children (24 boys and 13 girls) aged M = 7.61 ± 6.37 (1-22-years-old) were included in the research. A total of 44.7% are diagnosed with cystic fibrosis, 31.6% with phenylketonuria and 23.7% with hypothyroidism. Socio-demographic characteristics and psychological and medical data reported by mothers were registered to point the presence of some characteristics related to the diseases and to identify differences between the three categories of patients. Data have been processed using SPSS Statistics v23.0.0 for MAC.OSX. Results: Almost 1/5 of children diagnosed with hypothyroidism and phenylketonuria were found to have depression symp-toms and 1/3 of patients with hypothyroidism are having cognitive impairment associated in 40% of cases with language difficulties, and 20% of them present difficulties to adapt to so-cial environment. A total of 18.3% of children with cystic fibrosis presented enuresis and 20% of them has bruxism. Conclusions: children with rare disease present several psycho-logical symptoms and social difficulties, psychotherapeutically and educational support for both patients and families are needed.

References

1. deVrueh et al. Background Paper 6.19 Rare Diseases. World Health Organization, 2013. 2. ***EURORDIS. What is a rare disease? http://www.orpha.net/consor/cgi-bin/Education_About RareDiseases.php?lng=EN accessed March 2017. 3. ***EURORDIS. The Voice of 12.000 Patients. Paris, EURORDIS, 200922. 4. Aghasi P. et al. Intellectual and developmental status in children with hyperphenylalaninemia and PKU who were screened in a national program. Iran J Pediatr 2015; 25(6): e3033. 5. Medford E. et al. Treatment Adherence and Psychological Wellbeing in Maternal Care of Children with Phenylketonuria (PKU),1-8, 2017. 6. Borghi L. et al. Psychological and psychosocial implications for parenting a child with phenylke-tonuria: a systematic review. Minerva pediatrica 2017; doi: 10.23736/S0026-4946.17.04950-7. 7. Manti F. et al. Psychiatric disorders in adolescent and young adult patients with phenylketonu-ria. Molecular genetics and metabolism 2016; 117(1): 12-18. 8. Grody WW et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genetics Med 2001; 3(2): 149-154. 9. Grosse SD et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recom-mendations for state newborn screening programs, 2004. 10. Groose MK et al. (2010). Opportunities for quality improvement in cystic fibrosis newborn screen-ing. Journal of Cystic Fibrosis, 2010; 9(4): 284-287. 11. Gardner J. What you need to know about cystic fibrosis. Nursing 2017; 37(7): 52-55. 12. Wu T et al. Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC pediatrics 2006; 6(1):1. 13. Rovet JF & Ehrlich R. Psychoeducational outcome in children with early-treated congenital hypothy-roidism. Pediatrics 2000; 105(3): 515-522.
14. Fuggle PW et al. Intelligence, motor skills and behavior at 5 years in early-treated congenital hypothyroidism. European J Ped 1991; 150(8): 570-574.
15. Campos MLP et al. Cognitive profiles of patients with early detected and treated congenital hypothyroidism. Arch Argent Ped 2017; 115(1):12-17.
16. Bongers-Schokking JJ et al. Individualized treatment to optimize eventual cognitive outcome in congenital hypothyroidism. Ped Res 2016; 80(6): 816-823.
17. Zwaveling-Soonawala N. et al. The severity of congenital hypothyroidism of central origin should not be underestimated. J ClinEndocMetab2015; 100(2): E297-E300.
18. Bongers-Schokking JJ et al. Cognitive development in congenital hypothyroidism: is overtreatment a greater threat than undertreatment? J ClinEndocMetab 2013; 98(11): 4499-4506.
19. Anton-Paduraru DT, Iorga M. Ethical issues in cystic fibrosis. Rom J Ped 2015; 64(4): 393-397.
20. Anton-Pǎduraru Dana-Teodora et al. P362 Iron status in children with phenylketonuria from a regional center from North-eastern of Romania. Arch Dis Childhood 2017; 102(2): A173-A173.
21. Léger J.et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endoc Metab 2014; 99(2): 363-384.

Additional Files

Published

2017-09-30

Issue

Section

INTERNAL MEDICINE - PEDIATRICS